Capricor Therapeutics Inc. (CAPR), which recently received a setback from the FDA regarding its cell therapy for Duchenne muscular dystrophy, remains confident in its potential and is looking to the upcoming HOPE-3 trial results to support its regulatory progress.
The investigational treatment in focus, Deramiocel (CAP-1002), is made from allogeneic cardiosphere-derived cells (CDCs), a rare type of heart cell that has shown strong anti-inflammatory and anti-fibrotic effects in both preclinical and clinical studies. These effects help protect heart and muscle function in conditions like Duchenne muscular dystrophy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com